Previous Article | Next Article ![]()
Infection and Immunity, November 2004, p. 6642-6649, Vol. 72, No. 11
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.11.6642-6649.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
and
Steven M. Singer*
Department of Biology, Georgetown University, Washington, D.C.
Received 5 April 2004/ Returned for modification 22 May 2004/ Accepted 3 August 2004
|
|
|---|
|
|
|---|
Immunity to G. lamblia has been shown to occur in at least two distinct phases in mice. Normally mice eliminate this infection within 2 weeks. T cells and interleukin-6 (IL-6) are important in this early phase, since SCID mice, anti-CD4-treated mice, Tcrß gene-targeted mice, and IL-6-deficient mice all fail to control these infections within this time frame (2, 4, 29, 36). In contrast, antibodies are not necessary in this phase, as B-cell-deficient mice eliminate the majority of parasites within 2 weeks (29). If infections persist beyond this initial phase, a second phase of the immune response can occur. This is best seen in IL-6-deficient mice that eliminate the parasites between 4 and 8 weeks postinfection (36). This correlates with the appearance of antiparasite immunoglobulin A (IgA) antibodies in the intestinal fluid that react with all parasites present in a population expressing diverse surface antigens. The longer time required for antibody-dependent control of these infections is consistent with the ability of the parasite to undergo antigenic variation (23). B-cell-deficient mice lack this second phase of immunity and have extended low-level infections, further supporting a role for antibodies in the control of chronic infections (19, 32). Thus, an IL-6-dependent pathway can control the infection early on while a B-cell-dependent pathway plays a role later on and may be important for preventing chronic infections. Similarly, human patients with X-linked agammaglobulinemia or common variable immunodeficiency are at risk for chronic giardiasis.
Immunity to the related parasite Giardia muris is similar, although B cells appear to play a more important role earlier. Anti-IgM-treated mice and xid mutant mice have defects in controlling this infection, and Langford et al. and Snider et al. recently showed that B-cell-deficient mice and IgA-deficient mice have significant defects in controlling G. muris infection early on (19, 30, 31). Nevertheless, significant decreases in parasite numbers were observed between 1 and 3 weeks postinfection in the absence of antibodies, consistent with the existence of an antibody-independent mechanism for controlling this infection as well. T cells are also important in this model, since nude mice and anti-CD4-treated mice have defects controlling G. muris infection (16, 27).
Mast cell responses have been suggested in protection against both G. lamblia, and G. muris infections. Infections in gerbils with G. lamblia or in mice with G. muris have shown that mast cells accumulate in the small intestine following infection (15, 20, 34). In addition, mast cell-deficient (c-kitw/wf) mice were unable to control G. muris infections (8), suggesting that mast cell responses may be involved in controlling these infections. However, c-kit mutant animals exhibit multiple defects including anemia, abnormal 
T cell development, and an absence of intestinal pacemaking activity (13, 26, 28). Cyproheptadine (an antagonist of histamine H1 receptors) treatment prolonged infections with G. muris, suggesting that histamine release from mast cells may be involved in Giardia immunity (34). Importantly, attempts to reconstitute the mast cell response in the c-kitw/wf mice by adoptive transfer of bone marrow mast cells did not restore resistance to infection (8), and cyproheptadine has numerous effects unrelated to its antihistaminic properties, making it difficult to precisely implicate mast cells in resistance to Giardia infection based on these data.
We have therefore analyzed G. lamblia infections and mast cell and IgA responses in c-kit mutant as well as anti-c-kit-treated mice to determine whether mast cells have a role in T-cell-dependent immunity to Giardia. We have also examined infections and measured mast cell and IgA responses in IL-6 and IL-9 mutant mice to determine whether these cytokines are important for mast cell responses in the intestine during Giardia infections.
|
|
|---|
Parasites and infections. G. lamblia (strain GS/M/H7) was cultured and used for infections as previously described (36). Mice were infected by gavage with 5 x 105 to 10 x 105 parasites in phosphate-buffered saline (PBS), and parasite numbers in the small intestines were determined at different days postinfection. To count parasites, 10-cm sections of small intestine were minced in 4 ml of PBS, kept on ice for >30 min to release parasites, and counted on a hemocytometer. Because Giardia requires bile for growth, we routinely analyzed parasite numbers in the duodenum, beginning just distal to the junction of the small intestine with the common bile duct.
Mast cell blockade in vivo. Anti-c-kit rat IgG2b (ACK-2) (25) and control rat IgG2b (J1.2) were provided by Fred Finkelman (University of Cincinnati) as ammonium sulfate-purified ascites fluid. Mice were treated with 0.5 mg of antibody in 200 µl of PBS by intraperitoneal injection on days 2, 4, 6, and 8 postinfection. Mice were analyzed on day 10 postinfection.
Intestinal antibody responses. Intestinal washes were collected from the 5-cm segment of jejunum distal to that used for counting parasites by flushing the lumen with 0.5 ml of PBS/mouse. The presence of antiparasite antibodies was determined as previously described (36). Briefly, parasite cultures were allowed to attach to glass slides and fixed with cold methanol-acetone (1:1). Slides were blocked with 5% goat serum in PBS and then incubated with intestinal washes diluted 1:5 in PBS plus 5% goat serum, followed by goat anti-mouse IgA, goat anti-mouse IgG, or goat anti-mouse IgM conjugated to fluorescein isothiocyanate (Southern Biotechnology Associates, Birmingham, Ala.). Giardia-specific monoclonal antibodies of each isotype were used as controls for the specificity and sensitivity of each secondary reagent. Slides were mounted with Vectashield plus propidium iodide (Vector Laboratories, Burlingame, Calif.) and viewed with a Zeiss Axiophot microscope. Images were collected with a CoolSnap fx camera (Roper Scientific, Trenton, N.J.) by using OpenLab software (Improvision, Cambridge, Mass.). Images were processed with Photoshop (Adobe Systems, San Jose, Calif.).
Mast cell staining. Two- to three-centimeter segments of small intestine distal to the segment used for collecting parasites (after collection of intestinal washes) were fixed in 10% formalin, embedded in paraffin, and sectioned. Tissue sections were stained for chloroacetate esterase activity as described previously (12) and counterstained with hematoxylin. Slides were viewed as for the fluorescence microscopy, except that the microscope was also equipped with a CRI filter wheel (Cambridge Research, Cambridge, Mass.). Mast cell numbers were then determined by an observer who was unaware of the identities of the samples.
Serum histamine and mast cell protease measurements. Venous blood was collected from mice immediately prior to sacrifice and allowed to clot overnight at 4°C. Sera were collected after centrifugation and stored in aliquots at 20°C until tested. Histamine levels were measured in sera diluted 1:20 with PBS by using a competitive enzyme-linked immunosorbent assay system (Immunotech; Beckman Coulter, Fullerton, Calif.). Mouse mast cell protease levels were determined by capture enzyme-linked immunosorbent assay (Moredun Scientific, Midlothian, Scotland, United Kingdom).
RT-PCR. Small intestinal RNA was prepared from a 1- to 2-cm segment of the small intestine distal to that used for enumerating parasites. RNA was purified by using RNA-STAT-60 (Teltest, Inc., Midland, Tex.). Reverse transcription (RT) and amplification of IL-6 and hypoxanthine phosphoribosyltransferase cDNA were performed as described previously (36). Briefly, 5 µg of RNA was reverse transcribed with SuperScript II reverse transcriptase (Invitrogen, Carlsbad, Calif.). cDNA was then amplified with Taq polymerase and primers for hypoxanthine phosphoribosyltransferase to determine whether samples contained similar amounts of cDNA. IL-6 cDNA was then amplified and analyzed on 1.5% agarose gels in 0.5x Tris-borate-EDTA buffer.
Statistics. Data were analyzed by either the Student t test or the Mann-Whitney test. The nonparametric Mann-Whitney test was used when analyzing parasite numbers, since data were not normally distributed, and t tests were used for comparisons of mast cell numbers, histamine, and mast cell protease levels. Analyses were performed with GraphPad Prism (version 3.0cx; GraphPad Software, Inc., San Diego, Calif.). P values of <0.05 were considered significant.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. G. lamblia infections in mast cell-deficient mice
|
![]() View larger version (42K): [in a new window] |
FIG. 1. Intestinal IgA Responses in G. lamblia-infected mice. Intestinal fluid was collected from the jejuna of 14-day-old infected c-kit+/+ (A) or c-kitw/wv (B) mice and used to stain trophozoites from in vitro cultures of G. lamblia. Fluorescein isothiocyanate-conjugated anti-IgA was used to demonstrate the presence or absence of IgA in the intestinal fluid, and propidium iodide (data not shown) was used to identify the parasites.
|
![]() View larger version (161K): [in a new window] |
FIG. 2. Mast cell responses and infections in anti-c-kit-treated mice. C57BL/6J mice were not infected (A) or infected (B and C) with 106 G. lamblia trophozoites and treated on days 2, 4, 6, and 8 with either control IgG (B) or anti-c-kit antibody (C). On day 10 postinfection, small intestines were fixed in formalin and paraffin sections were stained for chloroacetate esterase activity (red) to visualize mast cells and counterstained with hematoxylin. Similar results were seen with 8 mice/group. (D) Parasite numbers were determined in C57BL/6J mice infected with Giardia for 10 days and untreated (diamonds), treated with anti-c-kit (triangles), or treated with control IgG (circles). Each symbol represents a single mouse (n = 8 mice/group). *, P < 0.05 compared to wild-type controls. Data are representative of the results from three independent experiments.
|
![]() View larger version (72K): [in a new window] |
FIG. 3. IgA responses in anti-c-kit-treated mice infected with G. lamblia. Intestinal washes from uninfected C57BL/6J mice (A), 10-day-old infected C57BL6/J mice treated with control antibody J1.2 (B), untreated (C), or treated with anti-c-kit antibody ACK-2 (D) were used to stain in vitro cultures of G. lamblia with an IgA-specific secondary antibody. IgA detection was performed on at least 8 mice/group with similar results. Data are representative of the results from three independent experiments.
|
|
View this table: [in a new window] |
TABLE 2. G. lamblia infections in C57BL/6, BALB/c, and IL-9-deficient BALB/c mice
|
![]() View larger version (15K): [in a new window] |
FIG. 4. Mast cell responses in IL-9-deficient mice. BALB/c, IL-9-deficient, and C57BL/6 mice were infected with 106 G. lamblia trophozoites, and mast cell numbers were determined at day 14 postinfection. Mast cell numbers were determined on coded slides for 4 mice/genotype. Numbers of mast cells per three microscope fields were counted rather than mast cells per 10 villus-crypt units, as in Fig. 5, since tissue sections from many of these mice did not contain complete villus-crypt units but were sagittal sections through villi. Means and standard deviations are shown. *, P < 0.05 compared to BALB/c mice. Data are representative of the results from two independent experiments.
|
![]() View larger version (12K): [in a new window] |
FIG. 5. Mast cell responses in IL-6-deficient mice. C57BL/6J (triangles) and B6.129S2-Il6tm1Kopf (squares) mice were infected with 500,000 G. lamblia trophozoites and sacrificed at different times postinfection. Mast cells were visualized as described for Fig. 2. The number of mast cells are shown as means and standard deviations for 4 mice/time point (A). Sera were collected from C57BL/6J (triangles) and B6.129S2-Il6tm1Kopf (squares) mice on day 10 postinfection (filled symbols) and uninfected mice (open symbols) and assayed for histamine (B) and MMCP-1 (C). *, P < 0.05 compared to wild-type controls. Data from panel A are representative of the results from three independent experiments.
|
|
View this table: [in a new window] |
TABLE 3. G. lamblia infections in IL-6-deficient mice
|
Mast cells as source of IL-6. Since IL-6 was not necessary for mast cell accumulation or activation, we next examined whether mast cells are in fact a source of IL-6 during Giardia infection. RT-PCR analysis of IL-6 mRNA from infected wild-type mice treated with anti-c-kit antibody to block the mast cell response shows that IL-6 mRNA levels are reduced in the absence of mast cells compared to infected mice treated with control IgG or not treated with antibody (Fig. 6). However, IL-6 mRNA levels in the anti-c-kit-treated infected mice still appear higher than those in uninfected mice. Mast cells are not the only source of this cytokine in the intestinal tract, and these data suggest that multiple cell types contribute to the IL-6 response in vivo. These data are consistent with the idea that mast cells are a source of IL-6 during Giardia infection and that this IL-6 production is important for control of the infection.
|
View larger version (14K): [in a new window] |
FIG. 6. IL-6 mRNA expression in mast cell-deficient mice. RNA was isolated from uninfected C57BL/6 mice (lane 1) and infected mice treated with no antibody (lane 2), with anti-c-kit antibody (lane 3) or with control IgG (lane 4). RNA was converted to cDNA, and IL-6 levels were determined from pooled samples (n = 4).
|
|
|
|---|
A previous study with c-kitw/wf mice infected with G. muris observed prolonged infections in this model (8). They were unable to restore immunity, however, by adoptive transfer of bone marrow-derived mast cells. We have found that c-kitw/wv mice also fail to eliminate G. lamblia infections as well as control mice. We have also documented a defect in parasite-specific IgA production in these mice. To our knowledge, this is the first report of a defect in antibody production in c-kit mutant mice. Furthermore, while the failure of these mice to eliminate parasites does not exclude a role for mast cells in this infection, it requires that a different approach be used to demonstrate a requirement for mast cells. Treatment with anti-c-kit antibodies clearly inhibited the elimination of parasites and blocked mast cell responses without reducing parasite-specific antibodies. This result supports the idea that mast cells are required, since ACK-2 treatment of adult mice did not inhibit the production of parasite-specific IgA nor does it interfere with intestinal motility coordinated by the interstitial cells of Cajal that innervate the intestinal musculature (17, 35). While ACK-2 treatment of adult mice does inhibit the development of spermatogonia, it is difficult to see how this could affect Giardia infection in the intestine. In addition, these experiments were done in female mice and ACK-2 treatment does not interfere with oocyst development.
Immunity to Giardia occurs in distinct phases. It was previously shown that IL-6 is important in the early immune response (36), and the data presented here argue that mast cells are also involved in this phase. It is therefore likely that mast cell responses function in the same pathway as IL-6. IL-6 is clearly not required for the accumulation of mast cells, since the number of mast cells observed in infected IL-6-deficient mice was roughly threefold greater than in wild-type mice. IL-6 is also not required for production of histamine or MMCP-1, as both were found in IL-6-deficient mice. It remains possible that IL-6 is required for the production of some other mediator made by mast cells and that this mediator is required for the control of infections. Alternatively, mast cell mediators in conjunction with IL-6 from an unknown source are required in concert to control this infection. The simplest connection between mast cells and IL-6 in this system, however, is that mast cell production of IL-6 itself is involved in the elimination of Giardia. Consistent with this idea, mice treated with anti-c-kit antibodies to prevent mast cell responses had lower levels of IL-6 mRNA in the small intestine than did controls. Other cell types may also be producing IL-6 during Giardia infections, however, and a blockade of mast cell responses did not completely eliminate the induction of IL-6 mRNA levels.
Our studies further support a role for antibody during the later phase, but not during the early phase, of control of G. lamblia infections in mice. Like IL-6-deficient mice, anti-c-kit-treated mice produced antiparasite IgA but failed to rapidly control this infection, indicating that antibodies are not sufficient early on. The failure of c-kitw/wv mice to produce antiparasite IgA and to control infections with G. lamblia, even after 4 months, highlights the importance of IgA in this second pathway. Similarly, Langford et al. recently found that IgA-deficient mice developed chronic infections with G. muris and G. lamblia, although a sharp drop in parasite numbers was seen early in these infections (19). In humans, chronic giardiasis is associated with hypogammaglobulinemias, including Bruton's agammaglobulinemia and common variable immunodeficiency (11), suggesting that IgA may also be important for the control of chronic infections in humans.
IL-9, but not IL-6, is involved in generating the mast cell response to Giardia infection. IL-9-deficient mice had approximately one-third as many mast cells in the small intestine as control mice following infection. This was far less of a difference than was previously seen in the lungs of IL-9-deficient mice after challenge with S. mansoni eggs (33). However, the absence of IL-9 had less of an effect on intestinal mast cell responses to Nippostrongylus brasiliensis (9). IL-4 was shown to compensate for the absence of IL-9 in these experiments. The elevated mast cell response seen in the IL-6-deficient mice is also consistent with a role for IL-4 in promoting mast cell responses, as increased expression of IL-4 was previously seen in G. lamblia-infected IL-6 mutant mice (2). Finally, the absence of mast cell responses in STAT-6-deficient mice infected with G. lamblia (S. M. Singer and Z. Petrin, unpublished data) indicates that IL-4 signaling is necessary for intestinal mast cell responses in this model.
Variable outcomes of infection have long been noted in human giardiasis. We observed that, at 5 days postinfection, the number of parasites observed in BALB/c mice was greater than that seen in C57BL/6 mice. Both strains, however, were able to reduce parasite loads below the limits of detection by 12 days postinfection. Similarly, G. muris infections resolve more quickly in C57BL/10 mice than in BALB/c mice (34). Indeed, anti-gamma interferon treatment delayed G. muris elimination in C57BL/10 mice but not in BALB/c mice (34). Differences between these strains in response to several other infections have been noted and usually correlate with elevated Th2 responses in BALB/c mice compared to Th1-biased responses in C57BL/6 or C57BL/10 mice (1). This is also consistent with the elevated IL-4 production noted in IL-6-deficient mice (2; E. Li and S. M. Singer, unpublished data).
Mast cell responses may contribute to the pathophysiology of giardiasis in addition to the control of infections. Symptoms of giardiasis include malabsorptive diarrhea, cramps, and nausea and are similar to those noted in food allergies, celiac disease, and other intestinal disorders. In several of these diseases and in several animal models, mast cells have been implicated in contributing to this pathology (reviewed in reference 10). In addition, analysis of human giardiasis patients has suggested a possible involvement of mast cell responses during symptomatic infections (5, 7). The increase in serum MMCP-1 and histamine levels observed after infection of C57BL/6 mice suggests that symptoms of giardiasis may be related to allergic processes. Consistent with this idea, giardiasis in humans has been reported to be associated with both allergic responses and chronic urticaria (6, 7, 22). The contribution of mast cells to the pathophysiology of giardiasis in patients clearly warrants further study.
We have shown that mast cells are important for rapidly controlling murine infection with the protozoan parasite G. lamblia. We have also shown that IL-6 controls this infection early on and that mast cells are likely an important source of IL-6 during this infection. Identification of these responses provides correlates of protection to enhance the design and evaluation of new vaccines. The importance of mast cell responses in this infection also suggests new strategies for coping with the symptoms of this infection. Finally, further study of the regulation of these responses should provide novel insights into the regulation of immunity and inflammation in the gastrointestinal tract.
We thank Andrew McKenzie for providing IL-9-deficient mice, Fred Finkelman for providing ACK-2 and J1.2 antibodies, the Lombardi Comprehensive Cancer Center Tissue Resource for the preparation of paraffin-embedded sections, Joseph Scofi for technical assistance, and Navreet Nanda and Ted Nash for helpful comments on the manuscript.
Present address: University of Ljubljana Medical School, 1104 Ljubljana, Slovenia. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»